Rise Advisors’s Tyra Biosciences TYRA Stock Holding History

Rise Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-49	Closed	-$686	–	1332
2025 Q3	$686	Buy	+49	New	+$559	﹤0.01%	1334

Other funds holding TYRA

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rise Advisors's TYRA Position: Q4 2025 in Review

Rise Advisors sold out of Tyra Biosciences (TYRA) in Q4 2025, closing a stake of 49 shares — an estimated $686 sold.

Rise Advisors first reported a position in TYRA in Q3 2025 and held it in 1 quarter. The position peaked at $686 in Q3 2025. 133 funds tracked by Wall St. Rank hold TYRA as of Q4 2025.

Rise Advisors reported no remaining Tyra Biosciences position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 49 Tyra Biosciences shares in Q4 2025, an estimated $686.
Rise Advisors first reported a position in Tyra Biosciences in Q3 2025 and held it in 1 quarter.
Rise Advisors's Tyra Biosciences position peaked at $686 in Q3 2025.
133 funds tracked by Wall St. Rank held Tyra Biosciences as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.